JP2025063038A5 - - Google Patents

Info

Publication number
JP2025063038A5
JP2025063038A5 JP2024220496A JP2024220496A JP2025063038A5 JP 2025063038 A5 JP2025063038 A5 JP 2025063038A5 JP 2024220496 A JP2024220496 A JP 2024220496A JP 2024220496 A JP2024220496 A JP 2024220496A JP 2025063038 A5 JP2025063038 A5 JP 2025063038A5
Authority
JP
Japan
Prior art keywords
seq
antibody
heavy chain
light chain
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024220496A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025063038A (ja
JP7860208B2 (ja
Filing date
Publication date
Priority claimed from JP2021535893A external-priority patent/JP7607564B2/ja
Application filed filed Critical
Publication of JP2025063038A publication Critical patent/JP2025063038A/ja
Publication of JP2025063038A5 publication Critical patent/JP2025063038A5/ja
Application granted granted Critical
Publication of JP7860208B2 publication Critical patent/JP7860208B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024220496A 2018-12-21 2024-12-17 Pmel17に対する抗体及びその結合体 Active JP7860208B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862783565P 2018-12-21 2018-12-21
US62/783,565 2018-12-21
US201962803110P 2019-02-08 2019-02-08
US62/803,110 2019-02-08
JP2021535893A JP7607564B2 (ja) 2018-12-21 2019-12-18 Pmel17に対する抗体及びその結合体
PCT/IB2019/001333 WO2020128612A2 (en) 2018-12-21 2019-12-18 Antibodies to pmel17 and conjugates thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021535893A Division JP7607564B2 (ja) 2018-12-21 2019-12-18 Pmel17に対する抗体及びその結合体

Publications (3)

Publication Number Publication Date
JP2025063038A JP2025063038A (ja) 2025-04-15
JP2025063038A5 true JP2025063038A5 (cg-RX-API-DMAC7.html) 2025-09-02
JP7860208B2 JP7860208B2 (ja) 2026-05-15

Family

ID=69723993

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021535893A Active JP7607564B2 (ja) 2018-12-21 2019-12-18 Pmel17に対する抗体及びその結合体
JP2024062582A Withdrawn JP2024088757A (ja) 2018-12-21 2024-04-09 Pmel17に対する抗体及びその結合体
JP2024220496A Active JP7860208B2 (ja) 2018-12-21 2024-12-17 Pmel17に対する抗体及びその結合体

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2021535893A Active JP7607564B2 (ja) 2018-12-21 2019-12-18 Pmel17に対する抗体及びその結合体
JP2024062582A Withdrawn JP2024088757A (ja) 2018-12-21 2024-04-09 Pmel17に対する抗体及びその結合体

Country Status (22)

Country Link
US (3) US11779649B2 (cg-RX-API-DMAC7.html)
EP (2) EP4406555A3 (cg-RX-API-DMAC7.html)
JP (3) JP7607564B2 (cg-RX-API-DMAC7.html)
KR (2) KR102972072B1 (cg-RX-API-DMAC7.html)
CN (3) CN118994402A (cg-RX-API-DMAC7.html)
AU (2) AU2019409132B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021011900A2 (cg-RX-API-DMAC7.html)
CA (2) CA3234463A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001607A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021007968A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210324A (cg-RX-API-DMAC7.html)
CU (1) CU20210047A7 (cg-RX-API-DMAC7.html)
EC (1) ECSP21044421A (cg-RX-API-DMAC7.html)
IL (1) IL284027A (cg-RX-API-DMAC7.html)
JO (1) JOP20210159A1 (cg-RX-API-DMAC7.html)
MX (2) MX2021007593A (cg-RX-API-DMAC7.html)
PE (1) PE20211296A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021551479A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202106629PA (cg-RX-API-DMAC7.html)
TW (2) TW202430573A (cg-RX-API-DMAC7.html)
UY (1) UY38520A (cg-RX-API-DMAC7.html)
WO (1) WO2020128612A2 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201591465A1 (ru) * 2013-02-08 2015-12-30 АйАрЭм ЭлЭлСи Специфичные участки для модификации антител для получения иммуноконъюгатов
CN111686085B (zh) * 2020-06-30 2022-09-06 贵州益佰女子大药厂有限责任公司 一种咽喉清喉制剂的制备方法
WO2022183185A1 (en) * 2021-02-23 2022-09-01 Pandion Operations, Inc. Pd-1 antibodies, polypeptides and uses thereof
AU2022258829A1 (en) 2021-04-16 2023-10-26 Novartis Ag Antibody drug conjugates and methods for making thereof
JP2025181023A (ja) 2024-05-31 2025-12-11 株式会社やまびこ 電動作業機
FR3164899A1 (fr) * 2024-07-24 2026-01-30 Skymab Biotherapeutics Conjugue anticorps-medicament et ses utilisations
CN120399078B (zh) * 2025-05-08 2026-03-06 上海天泽云泰生物医药股份有限公司 靶向cd117的纳米抗体及其应用
CN122325606A (zh) * 2026-06-08 2026-07-03 北京义翘神州科技股份有限公司 一种提高抗体偶联药物稳定性的方法以及半胱氨酸工程化抗体

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2429008A (en) 1945-12-01 1947-10-14 Diamond Chain & Mfg Company Sprocket or gear
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
EP0092918B1 (en) 1982-04-22 1988-10-19 Imperial Chemical Industries Plc Continuous release formulations
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
JPH06798B2 (ja) 1986-06-02 1994-01-05 藤沢薬品工業株式会社 Fr−900359物質およびその医薬として許容される塩
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
AU6430190A (en) 1989-10-10 1991-05-16 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
CA2071867A1 (en) 1989-11-06 1991-05-07 Edith Mathiowitz Method for producing protein microspheres
JPH06507404A (ja) 1991-05-01 1994-08-25 ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 感染性の呼吸性疾患の治療方法
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
EP0563475B1 (en) 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
ATE252894T1 (de) 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
AU710347B2 (en) 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US5985320A (en) 1996-03-04 1999-11-16 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
DE69732306T2 (de) 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド 人工抗体ポリペプチド
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2198922T3 (es) 1998-06-24 2004-02-01 Advanced Inhalation Research, Inc. Particulas porosas grandes emitadas por un inhalador.
HK1049997B (en) 1999-11-24 2007-02-23 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
AU767394C (en) 1999-12-29 2005-04-21 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
WO2004007529A2 (en) 2002-07-15 2004-01-22 The Trustees Of Princeton University Iap binding compounds
JP2003210190A (ja) 2002-01-18 2003-07-29 Yamanouchi Pharmaceut Co Ltd 環状ペプチド化合物とその製造法
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
BRPI0506883A (pt) 2004-01-16 2007-05-29 Univ Michigan miméticos de smac conformacionalmente comprimidos e seus usos
CN1933847A (zh) 2004-01-16 2007-03-21 密歇根大学董事会 Smac肽模拟物及其应用
US7345081B2 (en) 2004-03-23 2008-03-18 Genentech, Inc. Azabicyclo-octane inhibitors of IAP
PL2253614T3 (pl) 2004-04-07 2013-03-29 Novartis Ag Inhibitory IAP
KR100926203B1 (ko) 2004-07-02 2009-11-09 제넨테크, 인크. Iap의 억제제
WO2006010118A2 (en) 2004-07-09 2006-01-26 The Regents Of The University Of Michigan Conformationally constrained smac mimetics and the uses thereof
BRPI0513310A (pt) 2004-07-12 2008-05-06 Idun Pharmaceuticals Inc análogos de tetrapeptìdeo
JP5230865B2 (ja) 2004-07-15 2013-07-10 テトラロジック ファーマシューティカルズ コーポレーション Iap結合性化合物
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
MX2007007195A (es) 2004-12-20 2007-10-08 Genentech Inc Inhibidores de pirrolidina de iap.
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
KR20080080482A (ko) 2005-09-07 2008-09-04 메디뮨 엘엘씨 독소가 컨쥬게이트된 eph 수용체 항체
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
NZ598890A (en) 2007-04-30 2013-10-25 Genentech Inc Inhibitors of iap
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
BRPI0816769A2 (pt) 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
BRPI1015234A2 (en) 2009-06-22 2018-02-20 Medimmune Llc fc regions designed for site specific conjugation.
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
JP2013531469A (ja) 2010-04-16 2013-08-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 黒色腫におけるgna11およびgnaqのエキソン4変異
JP2015510200A (ja) 2012-02-20 2015-04-02 ノウリ コリア インコーポレイテッドKnowre Korea Inc. 知識ユニットに基づいて教育サービスを提供するための方法、システム、およびコンピュータ読み取り可能な記録媒体
GB201203051D0 (en) * 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203071D0 (en) * 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
KR20150006000A (ko) 2012-05-01 2015-01-15 제넨테크, 인크. 항-pmel17 항체 및 면역접합체
WO2013179174A1 (en) 2012-05-29 2013-12-05 Koninklijke Philips N.V. Lighting arrangement
SG11201407017WA (en) 2012-06-04 2014-12-30 Irm Llc Site-specific labeling methods and molecules produced thereby
EA201591465A1 (ru) 2013-02-08 2015-12-30 АйАрЭм ЭлЭлСи Специфичные участки для модификации антител для получения иммуноконъюгатов
WO2014124258A2 (en) 2013-02-08 2014-08-14 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
BR112016020065A2 (pt) 2014-03-12 2018-02-20 Novartis Ag sítios específicos para modificar anticorpos para fazer imunoconjugados
EA201691765A1 (ru) 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
EP3125943B1 (en) 2014-04-04 2026-04-22 Merck Sharp & Dohme LLC Phosphate based linkers for intracellular delivery of drug conjugates
GB201506870D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
MY199595A (en) * 2016-03-02 2023-11-08 Eisai R&D Man Co Ltd Eribulin-based antibody-drug conjugates and methods of use
CN108700598A (zh) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 多路总抗体和抗体缀合的药物量化测定法
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
JOP20190187A1 (ar) * 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
AR113224A1 (es) * 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
WO2018229162A1 (en) 2017-06-14 2018-12-20 Servizo Galego De Saúde In vitro method for detecting tumor growth and diagnosing or prognosticating the risk of metastasis in a human subject that has been diagnosed with uveal melanoma
WO2019060781A1 (en) 2017-09-22 2019-03-28 Washington University TARGETED PHARMACOLOGICAL THERAPEUTIC AGENTS IN UREAL MELANOMA
AU2022258829A1 (en) 2021-04-16 2023-10-26 Novartis Ag Antibody drug conjugates and methods for making thereof

Similar Documents

Publication Publication Date Title
JP2022515760A5 (cg-RX-API-DMAC7.html)
JP5231231B2 (ja) 複雑性が増大した生理活性アセンブリーを生成するための方法および組成物ならびに使用
JP2020506703A5 (cg-RX-API-DMAC7.html)
JP2024544520A5 (cg-RX-API-DMAC7.html)
JP2023539501A5 (cg-RX-API-DMAC7.html)
JP2022523710A5 (cg-RX-API-DMAC7.html)
CA2487060A1 (en) Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
JP2022514693A5 (cg-RX-API-DMAC7.html)
RU2017145150A (ru) Антитело против pdl-1, его фармацевтическая композиция и применение
JP2022550243A5 (cg-RX-API-DMAC7.html)
JP2022532173A5 (cg-RX-API-DMAC7.html)
EP4130046A1 (en) Platform for constructing multispecific antibody
JP2023542900A5 (cg-RX-API-DMAC7.html)
JP2023550419A5 (cg-RX-API-DMAC7.html)
TWI918721B (zh) Egfr結合複合物及其製備和使用方法
EP4206230A1 (en) Humanized antibody against digoxigenin and use thereof
FI4200018T3 (fi) Anti-par-2-vasta-aineet ja niiden käyttömenetelmät
JP2025513593A5 (cg-RX-API-DMAC7.html)
CN117177999B (zh) 一种靶向IL-18Rβ的抗体及其应用
JP7161490B2 (ja) アルデヒドを含有する標的分子を標識する方法
JP2023539246A5 (cg-RX-API-DMAC7.html)
CN117700558B (zh) 一种单克隆抗gprc5d抗体和抗gprc5d-car-nk细胞
RU2021121383A (ru) Антитела к рмel17 и конъюгаты на их основе
CN112159473A (zh) 重组人源化抗人白介素23单克隆抗体的纯化方法
WO2023125796A1 (en) Human antibodies against fap-alpha